United States - English - NLM (National Library of Medicine)

physicians total care, inc. - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.500 mg - mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of mirapex tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see clinical studies ). mirapex tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associated with symptoms of rls. mir

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - mirapexin is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

United States - English - NLM (National Library of Medicine)

rebel distributors corp - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.500 mg - mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of mirapex tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see clinical studies ). mirapex tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associated with symptoms of rls. mir

Philippines - English - FDA (Food And Drug Administration)

international apex pharmaceuticlas, inc.; distributor: international apex pharmaceuticlas, inc. - co-amoxiclav - film-coated tablet - 500mg/ 125mg

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - it is indicated for the correction of myopia and hyperopia. the lens is intended for single patient use and for daily wear.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - it is indicated for the correction of visual acuity in aphakic and non-aphakic persons with non-diseased eyes with myopia or hyperopia. the lens may be worn by persons who exhibit refractive astigmatism of 2.00 dioptres or less where the astigmatism does not interfere with visual acuity.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - it is indicated for the correction of refractive ametropia (myopia and hyperopia) in aphakic and non-aphakic persons with non-diseased eyes that may exhibit refractive and/or corneal astigmatism up to 2.00 dioptres that does not interfere with visual acuity.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - it is indicated for the correction of refractive ametropia (myopia and hyperopia) in aphakic and non-aphakic persons with non-diseased eyes that may exhibit refractive and/or corneal astigmatism up to 2.00 dioptres that does not interfere with visual acuity.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - it is indicated for the correction of visual acuity in aphakic and non-aphakic persons with non-diseased eyes with myopia or hyperopia. the lens maybe worn by persons who exhibit refractive astigmatism of 0.75 dioptres or less where the astigmatism does not interfere with visual acuity.

Singapore - English - HSA (Health Sciences Authority)

international contact lens pte. ltd. - ophthalmology - the icontact soft contact lenses for daily wear are indicated for the correction of myopia and hyperopia in aphakic or non-aphakic persons with non-diseased